Press release

December 21, 2010

Deinove foundation patent is soon to be granted by the European Patent Office

The European Patent Office is expected to grant the patent in Q1 2011. The European patent application EP2016183 covers the chromosome engineering process invented by Deinove cofounder Professor Miroslav Radman in 2006. This patent application served as the foundation for the incorporation of Deinove.

Paris, December 21, 2010 – Deinove (Alternext Paris: ALDEI), the world's leading specialist in Deinococcus bacteria for biofuels, green chemistry and antibiotics, today announced that the European Patent Office had notified it of the intention to grant the patent application *EP2016183* entitled "*Process for chromosome engineering using a novel DNA repair system".*

"The grant of our foundational, proprietary patent, coupled with the many additional patent applications filed since 2006, is important news. It provides worldwide protection for our technological developments and reinforces our global leadership in industrial exploitation of the deinococci, notably in biomass-derived biofuels, green chemistry and antibiotics", commented Chief Executive Officer Jacques Biton.

In 2006, the prestigious scientific journal *Nature*[1] reported the discovery by Miroslav Radman (a Professor at the Rene Descartes University of Paris and a member of the French Academy of Science) and his colleagues of the mechanism which enables the bacterium *Deinococcus radiodurans* to "come back to life" in a few hours by repairing and reorganizing its genetic material (DNA).

The patent filing protecting this major discovery prompted the incorporation of Deinove led jointly by Philippe Pouletty MD (Managing Partner at Truffle Capital) and Professor Radman.

The EP2016183 patent covers a genetic engineering process that exploits the deinococci's unique self-repair ability - a property that has enabled these bacteria to enrich their genome through natural evolution over 3 billion years. This self-repair process enabled them to develop the exceptional natural ability to exploit biomass by borrowing genes from other living organisms. The ability to integrate these survival genes has made the deinococci exceptional candidates for industrial exploitation.

In concrete terms, the grant of this patent will make Deinove the only company able to commercially exploit the *Deinococcus*-related genetic tools stemming from Miroslav Radman's major discovery and use them in industrial applications.

[1] ***"Reassembly of shattered chromosomes in* Deinococcus radiodurans" - Nature *advanced online publication, September 27, 2006***
Ksenija Zahradka, Dea Slade, Adriana Bailone, Suzanne Sommer, Dietrich Averbeck, Mirjana Petranovic, Ariel B. Lindner & Miroslav Radman

About Deinove

The greentech company Deinove (Alternext Paris: ALDEI) is dedicated to the development and commercial exploitation of innovative technological processes for the production of biofuels and other compounds of industrial or pharmaceutical interest, by exploiting the deinococci's exceptional natural properties. Deinove successfully floated on the Alternext stock market in April 2010. The company intends to leverage its proprietary bacterial strains, technologies and processes by outlicensing to industrial partners. Deinove has partnered with leading sugar, ethanol and starch company TEREOS in order to develop the Deinol project, which aims at producing cellulosic ethanol in existing industrial facilities.

Deinove currently has 23 staff and operates several collaborative R&D programmes with the CNRS (Montpellier and Marseilles), the University of Paris V, INSA Toulouse and the VTT in Finland. It was incorporated in late 2006 under the joint impetus of Philippe Pouletty MD (Managing Partner at the private equity firm Truffle Capital) and Professor Miroslav Radman (Professor of Cell Biology at Paris-Descartes University, a member of the French Academy of Science and winner of the 2003 INSERM Medical Research Prize). Professor Radman elucidated the genetic mechanism behind the extraordinary natural properties of the bacterium *Deinococcus* (biodiversity and robustness) on which Deinove's innovation strategy is based. The company's headquarters are in Paris and it operates a lab in Montpellier (Cap Alpha technopark), southern France.

For more information, visit www.deinove.com**.**

Disclaimer:

This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in Deinove ("the Company") in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in Chapter 4 of the Company's prospectus prepared in connection with its IPO and on which the French Autorité des Marches Financiers *("AMF") granted its visa no. 10-014 on March 25 2010, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.*
Updates are available on the company's website http://www.deinove.com

Contacts

ALIZE RP	*DEINOVE*
Caroline Carmagnol	*Angelita de Francisco*
Communication agency	*COO & strategic marketing*
Tel.: +33 142 68 86 43 / +33 664 18 99 59	*Tel.: +33 142 03 27 32 / + 33 607 15 28 87*
caroline@alizerp.com	*angelita@deinove.com*

Help protect the environment: if you wish to stay up to date with our corporate news and receive our newsletters in an electronic format, please send your contact details (including your e-mail address and phone number) to contact@deinove.com or subscribe to our RSS Feed on www.deinove.com.